Navigation Links
Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment
Date:4/14/2009

Expects to qualify for 180 days of sole marketing exclusivity

PITTSBURGH, April 14 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Hoffmann-La Roche Inc. in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Capecitabine Tablets, 150 mg and 500 mg, the generic version of Xeloda(R) Tablets, a chemotherapy treatment for breast and colorectal cancer.

Mylan believes it is the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for the product and expects to qualify for 180 days of sole marketing exclusivity once final FDA approval is obtained. Hoffmann-La Roche filed a lawsuit April 8 in the U.S. District Court for the District of New Jersey alleging infringement of U.S. Patent No. 5,472,949.

Xeloda Tablets, 150 mg and 500 mg, had approximately $447 million in sales for the 12 months ending Dec. 31, 2008, according to IMS Health. Currently, Mylan has 117 ANDAs pending FDA approval, 33 of which are potential first-to-file opportunities.

This press release includes statements that constitute "forward-looking statements," including with regard to the expected first-to-file status and pending litigation. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward- looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the use of legal, regulatory and legislative strategies by competitors or other third parties to de
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Andrew G. Cuneo Joins Mylan as Vice President of Global Business Development
2. Mylan Announces Clarinex(R) Settlement Agreement
3. Mylan Announces Intention to Purchase Remaining Interest in Matrix Laboratories and Delist Matrix from Indian Stock Exchanges
4. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
5. Mylans Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor
6. Mylan Announces Transition of Chief Financial Officer
7. Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell
8. Mylan Schedules Fourth Quarter Financial Results Conference Call and Live Webcast
9. Mylan Receives FDA Approval for First-to-File Generic Depakote(R) ER
10. Mylan Declares Quarterly Preferred Stock Dividend
11. Mylan Receives Final FDA Approvals for Generic Versions of Lamictal(R) Tablets and Lamictal(R) CD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... Steven Reinberg ... News) -- In a head-to-head comparison, an experimental drug ... and hospitalizations in heart failure patients. According to ... of the marked benefit of the new drug, dubbed ... those getting the standard medication, enalapril (Vasotec), either died ...
(Date:9/1/2014)... An operating theatre or operating room is ... operations. An operating room comprises a myriad of specially-designed ... lights, imaging displays as well as integration systems for ... Research, a U.S.-based market research firm, the operating room ... by 2019. , According to this report, the ...
(Date:9/1/2014)... Barcelona, Spain Monday 1 September 2014: Daily fruit ... up to 40%, according to research presented at ESC ... The findings from the seven year follow-up study of ... found that the more fruit people ate, the more ... "CVD, including ischaemic heart disease (IHD) and stroke, is ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Bioinformatics ... organize and analyze biological and genetic data. A ... activity of developing software tools to generate and ... be confused with biological computation. While bioinformatics simply ... of biology can its related concepts, biological computation ...
(Date:9/1/2014)... 2014 Ontraport , one of ... was developed to automate the small intricacies of managing ... Shane Michaels, prompting an investigative review. , “As ... of managing all of the small details involved with ... reports Michaels. “That’s why Ontraport has become so popular ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2
... , , , ... part of Mayo Clinic and Microsoft Corp.,s shared vision to help ... made enhancements to Mayo Clinic Health Manager , ... manage their health. People with conditions such as hypertension and high ...
... Germany: For the first time researchers have shown that by ... possible to make pancreatic cancer cells sensitive to chemotherapy, opening ... treat the disease. Dr Davide Melisi told Europe,s ... Berlin today (Thursday 24 September) that resistance to chemotherapy was ...
... New Series ... iPod touch. , ... (Vocus) September 24, 2009 -- Modality, Inc. and Elsevier, Inc. today announced two Procedures Consult ... help physicians, medical residents and students prepare for, perform and test their knowledge of the ...
... ... leader in automatic door sensors, BEA, Inc. is delighted our products will be welcoming ... center in the world with Gold LEED® (Leadership in Energy and Environmental Design) certification. ... Pittsburgh, Pa. ...
... ... is featured in a presentation and free downloadable slides on the Diabetes Best Practices ... Somerville, ... illnesses should focus on self-care and give them the survival skills necessary to maintain ...
... AMSTERDAM, September 24 Amsterdam Molecular,Therapeutics (Euronext: AMT), a ... Jorn Aldag as its new Chief Executive Officer, starting,October ... in the life,sciences sector and more than twenty five ... President and CEO of Evotec AG, he was,instrumental in ...
Cached Medicine News:Health News:Mayo Clinic Health Manager Now Includes Features for People Managing Hypertension and High Cholesterol 2Health News:Mayo Clinic Health Manager Now Includes Features for People Managing Hypertension and High Cholesterol 3Health News:Pancreatic cancer: Researchers find drug that reverses resistance to chemotherapy 2Health News:Procedures Consult Internal Medicine Applications Now Available on App Store 2Health News:Procedures Consult Internal Medicine Applications Now Available on App Store 3Health News:BEA Opens the Doors to the World at G20 Summit 2Health News:BEA Opens the Doors to the World at G20 Summit 3Health News:New Presentation Highlights Importance of In-Hospital Hyperglycemia Management and Appropriate Discharge Planning for Diabetes Patients 2Health News:AMT Appoints New Chief Executive Officer 2Health News:AMT Appoints New Chief Executive Officer 3
(Date:8/29/2014)... , Aug. 29, 2014  A Boston Scientific ... study on stent removability and preliminary long term ... published in the August issue of the peer-reviewed ... 1 is being conducted in 11 countries ... covered self-expanding metal stents (FCSEMS) after extended indwell ...
(Date:8/29/2014)... PLEASANTON, Calif. , Aug. 29, 2014 ... leader in device-based mechanical circulatory support therapies to save, ... be participating in the 2014 Morgan Stanley Global Healthcare ... F. Burbach , President and Chief Executive Officer, will ... p.m., Eastern Daylight Time (9:55 a.m., Pacific Daylight Time). ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Cancer Therapeutics Market & Pipeline Insight 2014" report ... developed to prevent and eradicate the prevalence of cancer ... are confined to low specificity, safety and large number ... for a better solution. It has been discovered that ...
Breaking Medicine Technology:Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2
For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
For the qualitative detection of group A streptococcal antigen from throat swabs....
For the qualitative detection of group A streptococcal antigen from throat swabs....
For the measurement of vaginal pH as part of a self examination programme to help reduce the risk of pre-term birth...
Medicine Products: